US 12,285,481 B2
Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein
Kayvan Niazi, Culver City, CA (US); and Thomas H. King, Culver City, CA (US)
Assigned to NantCell, Inc., Culver City, CA (US)
Filed by NantCell, Inc., Culver City, CA (US)
Filed on May 4, 2023, as Appl. No. 18/312,532.
Application 18/312,532 is a continuation of application No. 16/883,263, filed on May 26, 2020, granted, now 11,684,668.
Claims priority of provisional application 63/022,146, filed on May 8, 2020.
Claims priority of provisional application 63/016,241, filed on Apr. 27, 2020.
Claims priority of provisional application 63/016,048, filed on Apr. 27, 2020.
Claims priority of provisional application 63/010,010, filed on Apr. 14, 2020.
Claims priority of provisional application 63/009,960, filed on Apr. 14, 2020.
Claims priority of provisional application 62/991,504, filed on Mar. 18, 2020.
Claims priority of provisional application 62/988,328, filed on Mar. 11, 2020.
Prior Publication US 2023/0302121 A1, Sep. 28, 2023
Int. Cl. A61K 39/215 (2006.01); C07K 14/005 (2006.01); C07K 14/165 (2006.01); C12N 1/16 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01); A61K 39/235 (2006.01); C07K 14/81 (2006.01)
CPC A61K 39/215 (2013.01) [C07K 14/005 (2013.01); C07K 14/165 (2013.01); C12N 1/16 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 39/235 (2013.01); C07K 14/8103 (2013.01); C07K 2317/52 (2013.01); C07K 2319/01 (2013.01); C07K 2319/06 (2013.01); C12N 2710/10341 (2013.01); C12N 2770/20034 (2013.01); C12Y 304/17023 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method for inducing immunity in an individual, the method comprising administration to the individual a replication defective adenoviral serotype-5 (Ad5) vector comprising 1) an E1 gene region deletion, 2) an E2b gene region deletion, 3) a nucleic acid sequence that encodes a SARS-COV-2 S protein having the amino acid sequence of SEQ ID NO: 4, and 4) a nucleic acid sequence that encodes a chimeric protein comprising a SARS-COV-2 N protein having the amino acid sequence of SEQ ID NO: 1 and an endosomal targeting sequence having the amino acid sequence of SEQ ID NO: 2.